Dr. Scott A. Fretzin, MD

Dr. Fretzin practices at Dawes Fretzin Dermatology Group in Indianapolis, Indiana.

Dr. Fretzin's NPI, 1023011244, was assigned on May 23, 2005. Dr. Fretzin graduated from University of Chicago, Pritzker School of Medicine in 1993. Dr. Fretzin holds Indiana license 01044060B.

Dr. Fretzin's primary practice is Dawes Fretzin Dermatology Group, at 7910 N Shadeland Ave, Indianapolis, IN 46250 in Marion County. The practice phone is (317) 516-5000.

Dr. Fretzin's primary practice is Dawes Fretzin Dermatology Group in Indianapolis, Indiana. Dr. Fretzin is also affiliated with IU Health Methodist Hospital. The medical group on file is Dawes Fretzin Dermatology. Dmand AI also links Dr. Fretzin to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fretzin practices, 3 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Fretzin's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Fretzin is licensed in Indiana.

CMS data shows 15,262 Medicare services from Dr. Fretzin across 36 procedure codes in 2024, for 2,474 Medicare patients. Medicare paid $1,104,204 for them. Every service was in an office.

CMS counts 2,474 Medicare patients who saw Dr. Fretzin in 2024. The largest group is 65 to 74, with 1,271 patients. 75% of them have high cholesterol, and 70% have high blood pressure. 3% are also on Medicaid. Their average risk score is 1.03, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Fretzin's median patient age at 69, with 49% women.

In 2024, Dr. Fretzin wrote 2,883 Medicare Part D claims for 917 patients. 81% of them were for generic drugs. CMS names the drug for 2,671 of them, across 46 drugs with 11 or more claims each, at $3,651,784 in total drug cost. In 2023, CMS named 2,226 claims across 44 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Fretzin for performance year 2024, reported as part of a group. Dr. Fretzin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 2,218 procedures of removal of skin lesions by Dr. Fretzin, more than 98% of the clinicians it reports for that procedure.

Removal of nail tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 5 papers to Dr. Fretzin, published from 2012 to 2025. The most frequent topics are Antibodies, Monoclonal, Humanized and Double-Blind Method. Dr. Fretzin's most frequent co-authors are Lindsay Skye Ackerman, MD, Subhashis Banerjee, MD and Jennifer Clay Cather, MD.

Dmand AI links Dr. Fretzin to 20 clinical trials, 3 of them phase 2 studies. Conditions studied include Dermatitis, Atopic, Psoriasis and Skin Diseases, Papulosquamous. Eli Lilly and Company sponsors the most, 11. Open Payments lists research payments to Dr. Fretzin that name 13 trials.

CMS Open Payments shows 2,643 general payments to Dr. Fretzin from 44 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 82% of the total. Eli Lilly and Company paid the most, $246,176. It also lists 47 research payments totaling $86,669 from 2016 to 2025, naming 13 clinical trials.

Dr. Fretzin graduated from University of Chicago, Pritzker School of Medicine in 1993.